Sagility Q2 FY27 Results: Consolidated Net Profit ₹284 Crore on Total Income of ₹2,045 Crore
Earnings
Healthcare operations (BPM)
Blacklitt Research4 min read
Sagility Ltd. reported consolidated total income of ₹2,044.95 crore and net profit of ₹284.21 crore for the quarter ended 30 Sep 2026. Standalone total income for the same quarter was ₹592.06 crore and standalone net profit was ₹97.94 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹2,044.95 crore, up 19.1% YoY and 3.4% QoQ
Net profit and EPS: ₹284.21 crore, up 13.3% YoY; basic EPS ₹0.61 against ₹0.53 a year earlier
Finance costs: ₹18.54 crore, down 25.8% YoY; 0.9% of total income this quarter
Exceptional items: None in the quarter; a ₹15.09 crore exceptional item sits in the June 2026 quarter
Standalone
The company on its own, without its subsidiaries
Total income: ₹592.06 crore, up 14.2% YoY and 6.5% QoQ
Net profit and EPS: ₹97.94 crore, down 11.6% YoY; basic EPS ₹0.21 against ₹0.23 a year earlier
Other income: ₹16.91 crore, down 36.6% YoY; 2.9% of total income this quarter
Finance costs: ₹12.76 crore, down 30.0% YoY
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
2,044.95
1,716.66
+19.1%
1,977.81
+3.4%
Revenue from operations
2,032.10
1,658.49
+22.5%
1,963.49
+3.5%
Other income
12.85
58.17
-77.9%
14.32
-10.3%
284.21
250.83
+13.3%
216.81
+31.1%
Finance costs
18.54
24.99
-25.8%
21.89
-15.3%
Depreciation
132.40
121.51
+9.0%
128.03
+3.4%
Tax expense
90.01
75.98
+18.5%
70.67
+27.4%
Net profit margin
13.90%
14.61%
-0.71 pp
10.96%
+2.94 pp
Tax as share of profit before tax
24.1%
23.2%
+0.80 pp
24.6%
-0.53 pp
EPS, basic (₹)
0.61
0.53
+15.1%
0.46
+32.6%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit rose 13.3% YoY, slower than total income, which rose 19.1%. Revenue from operations rose 22.5%, from ₹1,658.49 crore to ₹2,032.10 crore, while other income fell 77.9%, from ₹58.17 crore to ₹12.85 crore. Other income is now 0.6% of total income this quarter.
Profit before tax for the quarter is ₹374.22 crore, with no exceptional item shown for the quarter. Tax expense is ₹90.01 crore, a tax share of 24.1% of profit before tax, against 23.2% a year earlier. The June 2026 quarter carries a ₹15.09 crore exceptional item, which the filing records as past service cost on gratuity and leave encashment, following the revised Karnataka and Telangana minimum wage rates.
Net profit rose 31.1% QoQ, faster than total income at 3.4%. Finance costs fell 25.8% YoY to ₹18.54 crore, and depreciation rose 9.0% to ₹132.40 crore. Finance costs are 0.9% of total income this quarter.
The CareSeed LLC acquisition, completed on 11 Jun 2026, carries a total contractual consideration of ₹287.34 crore, including contingent consideration of up to USD 12.5 million. The provisional goodwill is ₹150.76 crore, allocated to the Payer CGU. After the quarter, on 21 Oct 2026, the group signed a definitive agreement to acquire Chirok Health LLC for ₹310.24 crore, including contingent consideration; the closing conditions had not been met at the Board date.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
592.06
518.35
+14.2%
555.80
+6.5%
Revenue from operations
575.15
491.68
+17.0%
538.96
+6.7%
Other income
16.91
26.67
-36.6%
16.84
+0.4%
97.94
110.84
-11.6%
75.98
+28.9%
Finance costs
12.76
18.22
-30.0%
15.80
-19.2%
Depreciation
23.78
21.13
+12.5%
23.25
+2.3%
Tax expense
32.05
34.33
-6.6%
25.38
+26.3%
Net profit margin
16.54%
21.38%
-4.84 pp
13.67%
+2.87 pp
Tax as share of profit before tax
24.7%
23.6%
+1.01 pp
25.0%
-0.39 pp
EPS, basic (₹)
0.21
0.23
-8.7%
0.16
+31.2%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit fell 11.6% YoY to ₹97.94 crore, while total income rose 14.2% to ₹592.06 crore. Revenue from operations rose 17.0% to ₹575.15 crore, and other income fell 36.6% to ₹16.91 crore. Tax expense fell 6.6% to ₹32.05 crore, and the tax share of profit before tax is 24.7%, against 23.6% a year earlier.
Standalone net profit rose 28.9% QoQ, faster than total income at 6.5%. Finance costs fell 30.0% YoY to ₹12.76 crore, and depreciation rose 12.5% to ₹23.78 crore. Other income is 2.9% of total income this quarter.
The consolidated net profit of ₹284.21 crore is ₹186.27 crore higher than the standalone figure of ₹97.94 crore. Consolidated net profit rose 13.3% YoY while standalone net profit fell 11.6%. The printed consolidated Other equity line does not match the sum of the balance sheet components, and the standalone Other equity line is also below its balance sheet components.
The Board approved an interim dividend of ₹0.15 per equity share on 22 Oct 2026, with a record date of 30 Oct 2026 and payment on or before 21 Nov 2026. The estimated cash outflow is about ₹70.22 crore. The company says the previous interim dividend was ₹0.05 per share. The final dividend of ₹0.10 for FY26 was paid in the quarter.
Inference
The interim dividend of ₹0.15 per share is about ₹70.22 crore in cash, and it is payable after the record date of 30 Oct 2026. The Chirok Health acquisition, at ₹310.24 crore including contingent consideration, was signed after the quarter and had not closed at the Board date; the filing does not say how it will be funded.
The CareSeed purchase accounting is provisional, and the contingent consideration on CareSeed and Chirok depends on performance targets. The filing does not say what drove the fall in other income or in standalone profit, and it does not say when the state-level Labour Code rules will be finalised; the company says it continues to monitor them.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
